Search
image1
HomeProductsCompanyInvestorsNewsSupportContactblog
CELLAVISION AB (publ) - Interim report for the period January 1 - March 31, 2009
2009-04-27
English
Continued strong sales trend during the first quarter of 2009
  •    Net sales for the quarter rose by 19% to SEK 22.0 million (18.5).
  •    The operating profit for the period was SEK 0.9 million (1.3).
  •    Earnings per share for the period amounted to SEK 0.02 (0.05).
  •    Cash and cash equivalents amounted to SEK 14.5 million (16.1) by the end of the quarter.
  •    CellaVision qualified for trade on NASDAQ OMX First North Premier on February 16, 2009.
  •  
    Important events after the reporting period
  •    The Japanese subsidiary received its first order.
  •    David Autry was appointed President of CellaVision North America.
  •    CellaVision was nominated for the SwedenBIO Award for its successes during 2008.
  •  
     
     
     
    CEO's comment
    "The first quarter indicates a continued strong sales growth, and we are still dedicated to our aim of furthering growth and profit in 2009," says Yvonne Mårtensson, CEO of CellaVision. "As yet, the financial crisis has not translated into a loss of orders; however, the purchasing processes tend to take longer for hospital customers. North America accounted for the majority of sales during this quarter, and Dave Autry has now been appointed President of our North American operations."
     
    "It is also satisfying to report that our Japanese subsidiary received its first order in April from the hospital laboratory in Tokyo that has been evaluating the product for some time. The laboratory at Tokyo Medical Center is a good reference to have in our future penetration of the important Japanese market."
     
    "Our growth is also owing to technological development. The development of a new hardware platform has reached an intense phase of prototype assembling and testing. This has resulted in increased costs, which in turn has an effect on results despite the fact the SEK 4.8 million was capitalized as expenditure for development. The main parts of these costs are now taken. A new product based on the new hardware platform will be launched in the second half of this year."
     
    Yvonne Mårtensson
    CEO CellaVision AB
     
     
    For more information please contact: 
    Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.com 
    Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.com
     
     
    Download the report by pressing the link below.

    Interim report for the period January 1 - March 31, 2009
    Archive

    2014
    2013
    2012
    2011
    2010
    2009
    2008
    2007
    2006
    2005
    2004
    2002